International Journal of Antimicrobial Agents
Volume 34, Issue 3 , Pages 205-209 , September 2009

Consensus statement on the management of invasive candidiasis in Intensive Care Units in the Asia-Pacific Region

  • Po-Ren Hsueh

      Affiliations

    • Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 2 2312 3456x5355; fax: +886 2 2322 4263.
    • ,
  • John Richard Graybill

      Affiliations

    • University of Texas Health Science Center, Infectious Diseases Division, TX, USA
    • ,
  • E. Geoffrey Playford

      Affiliations

    • Princess Alexandra Hospital, Qld, Australia
    • ,
  • Siriorn Paritpokee Watcharananan

      Affiliations

    • Ramathibodi Hospital, Bangkok, Thailand
    • ,
  • Myoung-Don Oh

      Affiliations

    • Seoul National University College of Medicine, South Korea
    • ,
  • Kamarudin Ja’alam

      Affiliations

    • Universiti Sains Malaysia, School of Medical Sciences, Kubang Kerian, Kelantan, Malaysia
    • ,
  • Shunwei Huang

      Affiliations

    • The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
    • ,
  • Vivek Nangia

      Affiliations

    • Batra Hospital and Medical Research Center, Delhi, India
    • ,
  • Asok Kurup

      Affiliations

    • Singapore General Hospital, Singapore
    • ,
  • Alexander Angelo Padiglione

      Affiliations

    • Monash Medical Centre, Vic, Australia

Received 16 March 2009 ,Accepted 17 March 2009.

References 

  1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317
  2. Hsueh PR, Chen ML, Sun CC, Chen WH, Pan HJ, Yang LS, et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan 1981–1999. Emerg Infect Dis. 2002;8:63–68
  3. Wu CJ, Lee HC, Lee NY, Ko NY, Wang LR, Ko WC. Predominance of Gram-negative bacilli and increasing antimicrobial resistance in nosocomial bloodstream infections at a university hospital in southern Taiwan 1996–2003. J Microbiol Immunol Infect. 2006;39:135–143
  4. Frank M, Gur E, Givon-Lavi N, Peled N, Dagan R, Leibovitz E. Nosocomial bloodstream infections in children and adolescents in southern Israel: a 10-year prospective study (1992–2001). Scand J Infect Dis. 2005;37:177–183
  5. Ronveaux O, Jans B, Suetens C, Carsauw H. Epidemiology of nosocomial bloodstream infections in Belgium 1992–1996. Eur J Clin Microbiol Infect Dis. 1998;17:695–700
  6. Hsueh PR, Teng LJ, Yang PC, Ho SW, Luh KT. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb Drug Resist. 2002;8:311–319
  7. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–163
  8. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J. 1998;17:504–508
  9. Voss A, le Noble JL, Verduyn Lunel FM, Foudraine NA, Meis JF. Candidemia in intensive care unit patients: risk factors for mortality. Infection. 1997;25:8–11
  10. Marchetti O, Bille J, Fluckiger U, Eggiman P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends 1991–2000. Clin Infect Dis. 2004;38:311–320
  11. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med. 2002;113:480–485
  12. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study. J Clin Microbiol. 2002;40:1298–1302
  13. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999;29:253–258
  14. Nakamura T, Takahashi H. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J Infect Chemother. 2006;12:132–138
  15. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother. 2004;53:283–289
  16. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg DA, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med. 2008;36:1993–1998
  17. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol. 2004;42:3142–3146
  18. Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol. 2005;43:5848–5859
  19. Ruan SY, Huang YT, Chu CC, Yu CJ, Hsueh PR. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes. Int J Antimicrob Agents 2009 Apr 8. [Epub ahead of print] PMID: 19361960.
  20. Yang CW, Barkham TM, Chan FY, Wang Y. Prevalence of Candida species, including Candida dubliniensis, in Singapore. J Clin Microbiol. 2003;41:472–474
  21. Ruan SY, Lee LN, Jerng JS, Yu CJ, Hsueh PR. Candida glabrata fungaemia in intensive care units. Clin Microbiol Infect. 2008;14:136–140
  22. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–3645
  23. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25–31
  24. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066–1072
  25. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233:542–548
  26. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Results of Candida prophylaxis in ICU patients. Intensive Care Med. 2002;28:1708–1717
  27. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother. 2006;52:628–638
  28. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685–702
  29. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med. 2006;34:857–863
  30. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis. 2007;26:271–276
  31. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751–758
  32. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system (‘Candida score’) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730–737
  33. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med. 2004;32:2443–2449
  34. Takesue Y, Kakehashi M, Ohge H, Imamura Y, Murakami Y, Sasaki M, et al. Combined assessment of β-d-glucan and degree of Candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg. 2004;28:625–630
  35. Schuster MG, Edwards JE, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149:83–90
  36. Golan Y, Wolf M, Pauker S, Wong J, Hadley S. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med. 2005;143:857–869
  37. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for the treatment of candidiasis. Clin Infect Dis. 2004;38:161–189
  38. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, et al. Guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–535

PII: S0924-8579(09)00147-2

doi: 10.1016/j.ijantimicag.2009.03.014

International Journal of Antimicrobial Agents
Volume 34, Issue 3 , Pages 205-209 , September 2009

Article Tools

* Image Usage & Resolution